2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 03:06, 16 November 2023
, 16 November 2023→Clinical Trials
| Line 154: | Line 154: | ||
==Clinical Trials== | ==Clinical Trials== | ||
{| class="wikitable" | Starting in 2020, with the assessment of the safety of a single dose administration of NMN, there have been around 10 randomized controlled trials (RCTs) exploring the compound's effects in various contexts. The trials have varied in duration, with the longest running for 12 weeks. In terms of dosage, they have explored a range of quantities, with the highest being 1,250 mg of NMN per day and 2,000 mg (2 g) of MIB-626, a specific formulation of NMN, per day. The following table provides a comprehensive overview of these trials, detailing their design, participant demographics, dosages, and key findings: | ||
{| class="wikitable mw-collapsible mw-collapsed" | |||
|+ | |+ | ||
! | Clinical Trials of NMN | ||
!Clinical Trial | |||
!Design | !Design | ||
!Participants | !Participants | ||